コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 kers have vascular protective effects beyond blood pressure lowering.
2 lt of CHF, even in the setting of aggressive blood pressure lowering.
3 at with losartan monotherapy, independent of blood pressure lowering.
4 e vast amount of evidence on the benefits of blood pressure lowering accumulated to date, elevated bl
5 ral bioavailability in rats and demonstrated blood pressure lowering activity in the double-transgeni
6 l dogs to assess its biological actions as a blood pressure-lowering agent and as a natriuretic facto
7 mised trials from around the world comparing blood pressure-lowering agents in adults with diabetic k
8 s a factorial randomized controlled trial of blood pressure lowering and blood glucose control in pat
9 r likelihood of new-onset AF, independent of blood pressure lowering and treatment modality in essent
10 f CV morbidity and mortality, independent of blood pressure lowering and treatment modality in person
12 that a novel conjugated oral hBNP possesses blood pressure-lowering and natriuretic actions over a 6
13 erapy (polypill) that combines antiplatelet, blood pressure-lowering, and cholesterol-lowering medica
14 eview focuses on the role of lipid-lowering, blood pressure-lowering, antithrombotic drugs and diet a
15 he Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) compared amlodi
16 he Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) show significan
17 e Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm (ASCOT-BPLA) whose BP remain
20 iting picomolar binding affinity and in vivo blood pressure lowering at pharmaceutically relevant dos
21 ve important mechanisms of action apart from blood pressure lowering but also that effective treatmen
22 t-trial follow-up for a median of 5.9 years (blood-pressure-lowering comparison) or 5.4 years (glucos
23 rtension from households able to afford four blood pressure-lowering drug classes were more likely to
25 -controlled trials of 4 different classes of blood pressure-lowering drugs (thiazides, beta-blockers,
26 were 17,641 participants who were allocated blood pressure-lowering drugs and 6603 who were allocate
27 a quadpill-a single capsule containing four blood pressure-lowering drugs each at quarter-dose (irbe
28 ct from the practical benefits of the use of blood pressure-lowering drugs in preventing headaches an
29 med to investigate the benefits and harms of blood pressure-lowering drugs in this population of pati
32 The availability of two or more classes of blood pressure-lowering drugs was lower in low-income an
33 pressure >/=140/90 mm Hg or those receiving blood pressure-lowering drugs) had a lifetime risk of ov
37 y disease) who were receiving at least three blood-pressure-lowering drugs, including a diuretic, at
38 hypothalamic NPYergic mechanisms mediate the blood pressure lowering effect of caloric restriction in
39 ypertension in mice and exerts a significant blood pressure lowering effect on preexisting hypertensi
40 r the renal protection, independent from its blood pressure lowering effect, have not yet been fully
42 hose affecting BNP did not, highlighting the blood pressure-lowering effect of ANP in the general pop
44 e effect of kallistatin yet it abolished the blood pressure-lowering effect of kinin and kallikrein.
50 new class of direct renin inhibitors exerted blood pressure lowering effects in a hypertensive double
51 ber indicate that the strongest evidence for blood pressure lowering effects is in hypertensive as op
54 e of 80-89 mm Hg to test the feasibility and blood pressure-lowering effects of seven nonpharmacologi
56 m vegetables and fruit may contribute to the blood pressure-lowering effects of the Dietary Approache
58 n contrast, in monkeys, EGF had dose-related blood pressure-lowering effects only; significant hypote
61 Denervation for Hypertension) confirmed the blood pressure-lowering efficacy of renal denervation ad
62 rovide biological proof of principle for the blood-pressure-lowering efficacy of renal denervation.
64 an event rate of 1.2% per year in intensive blood pressure-lowering group participants, compared wit
65 istent across patient groups, and additional blood pressure lowering had a clear benefit even in pati
66 vity profile and demonstrated robust in vivo blood pressure lowering in a spontaneously hypertensive
67 icyclic thiazepinone, demonstrated excellent blood pressure lowering in a variety of animal models ch
71 geted hemorrhagic shock, icatibant prevented blood pressure lowering in the angiotensin-converting en
72 based renal denervation produced significant blood pressure lowering in treatment-resistant patients
73 are additional benefits from more intensive blood pressure lowering, including for those with systol
76 )albuminuria, the use of lipid-modifying and blood pressure-lowering medication, and prior cardiovasc
78 d-lowering (19.2% versus 4.8%; P<0.001), and blood pressure-lowering medications (23.3% versus 12.1%;
79 s, treatment was based on the regular use of blood pressure-lowering medications, and control was def
81 ailable were more likely to use at least one blood pressure-lowering medicine (adjusted odds ratio [O
82 classes were more likely to use at least one blood pressure-lowering medicine (adjusted OR 1.42, 95%
83 ountries do not have access to more than one blood pressure-lowering medicine and, when available, th
85 roportion of households unable to afford two blood pressure-lowering medicines was 31% in low-income
86 0.0001) than were those in communities where blood pressure-lowering medicines were not available.
87 he availability, costs, and affordability of blood pressure-lowering medicines with data recorded fro
88 assess the availability and affordability of blood pressure-lowering medicines, and the association w
89 vascular disease (a statin, aspirin, and two blood-pressure-lowering medicines) in 23 such countries.
91 ne system inhibiting, cardiac unloading, and blood pressure lowering properties when compared with na
92 s of BTPs points toward antiinflammatory and blood pressure-lowering properties and improvement in pl
98 nts uncertainty about whether more intensive blood pressure-lowering strategies are associated with g
99 These findings emphasise the need for new blood pressure-lowering strategies, and will help to inf
102 sive low-density lipoprotein cholesterol and blood pressure lowering therapy slowed disease progressi
105 hat the main driver of clinical benefit from blood pressure-lowering therapy is the magnitude of bloo
106 served among patients originally assigned to blood-pressure-lowering therapy were attenuated but stil
107 In PAD patients with diabetes, intensive blood pressure lowering to a mean of 128/75 mm Hg result
109 pressures less than 130 mm Hg and providing blood pressure lowering treatment to individuals with a
112 he benefit or risk associated with intensive blood pressure-lowering treatment can be established onl
113 andomisation, patients in the more intensive blood pressure-lowering treatment group had mean blood p
114 w of evidence that the risks and benefits of blood pressure-lowering treatment in acute stroke might
115 s that caution should be taken in the use of blood pressure-lowering treatment in patients with coron
116 n or placebo therapy was not modified by the blood pressure-lowering treatment strategy in the factor
118 ants to more intensive versus less intensive blood pressure-lowering treatment, with different blood
119 been observed in the group receiving active blood-pressure-lowering treatment during the trial were
120 alizations for heart failure, independent of blood pressure lowering, treatment method, and other ris
123 nalysis, we searched MEDLINE for large-scale blood pressure lowering trials, published between Jan 1,
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。